Nurtec ODT (Rimegepant): Dual Acute and Preventive Migraine Treatment for Personal Injury Patients

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | April 14, 2025 | 7 min read

Nurtec ODT (rimegepant) is the only migraine medication FDA-approved for both acute treatment and preventive therapy. For personal injury patients with post-traumatic migraine, this dual capability means fewer prescriptions and a clear clinical record of ongoing migraine management following an accident.

Nurtec ODT (Rimegepant): Dual Acute and Preventive Migraine Treatment for Personal Injury Patients

Among the new class of CGRP-targeting migraine medications, Nurtec ODT (rimegepant) holds a unique position: it is the only drug in its class FDA-approved for both the acute treatment of migraine attacks and the preventive reduction of migraine frequency. This dual approval makes it particularly valuable for personal injury patients, who often present with both ongoing acute attacks and a pattern of increased headache frequency following trauma.

[!KEY] Nurtec ODT (rimegepant) is the only CGRP medication FDA-approved for both acute migraine treatment and prevention — a single prescription covers both clinical needs, creating a monthly refill record that documents persistent post-traumatic migraine management.

[!SOURCE] FDA CGRP Drug Approvals — FDA-approved CGRP antagonists for migraine prevention and treatment.

What Nurtec ODT Is

Rimegepant is an oral gepant — a small-molecule CGRP receptor antagonist that blocks the CGRP pathway responsible for migraine. Like the other gepants (atogepant/Qulipta, ubrogepant/Ubrelvy), it targets the calcitonin gene-related peptide receptor that drives neurogenic inflammation and vasodilation during migraine attacks.

The distinctive feature of Nurtec ODT is its formulation: it is an orally dissolving tablet (ODT) that dissolves under the tongue, without requiring water. This is clinically meaningful for migraine patients who commonly experience significant nausea during attacks and may struggle to swallow a conventional tablet.

The Dual FDA Approvals

Acute treatment (approved 2020): Nurtec ODT 75mg taken at the onset of a migraine attack. A second dose can be taken after 48 hours if needed. It does not require taking on a schedule — it is taken as needed for individual attacks.

Preventive treatment (approved 2021): Nurtec ODT 75mg taken every other day continuously for migraine prevention. This every-other-day regimen is what produces the preventive effect — the sustained presence of rimegepant maintains consistent CGRP receptor blockade between doses.

The same 75mg tablet and the same drug serve both purposes, making this the most versatile single-drug option in the CGRP class. A physician can prescribe Nurtec ODT and, based on how frequently the patient takes it, address both acute attacks and prevention simultaneously.

How the Every-Other-Day Regimen Works Clinically

The pharmacokinetics of rimegepant support the every-other-day preventive regimen. Rimegepant has a half-life of approximately 11 hours, but its active metabolite has a significantly longer half-life, extending the drug's receptor-blocking activity. Alternating-day dosing maintains sufficient drug concentrations to provide ongoing CGRP pathway inhibition without requiring daily dosing.

For patients who also need acute rescue on non-preventive days — which the every-other-day schedule allows — Nurtec ODT can be taken on the opposite day from the prevention dose if a migraine attack occurs. This flexible scheduling makes it practical to implement in real-world clinical settings.

Why Post-Traumatic Migraine Patients Benefit

Personal injury patients who develop post-traumatic migraine face a specific clinical pattern: they often have both frequent, unpredictable acute attacks that need immediate relief AND an underlying elevated migraine frequency that requires systematic prevention.

Older treatment paradigms required separate medications for these two needs — a separate preventive (topiramate, propranolol, amitriptyline) plus a separate acute rescue (triptan, NSAID). Each medication brought its own side effects, contraindications, and prescribing complexity.

Nurtec ODT simplifies this substantially. A neurologist treating a PI patient with post-traumatic migraine occurring 8-10 times per month can prescribe a single medication that:

• Treats acute attacks on the days they occur
• Provides preventive coverage through the alternating-day regimen
• Is well-tolerated with a safety profile superior to older preventive options

Clinical Evidence

CONQUER trial (acute treatment): Rimegepant demonstrated statistically significant pain freedom at 2 hours (19.6% vs. 12% placebo) and freedom from most bothersome symptoms (35.1% vs. 26.8% placebo). Clinical trials of acute migraine medications that meet both co-primary endpoints are considered robust evidence of efficacy.

BHV3000-201 trial (preventive): Patients taking rimegepant every other day experienced a mean reduction of 4.3 migraine days per month compared to 3.5 for placebo — a statistically significant difference. More meaningfully, 49% of rimegepant patients achieved at least a 50% reduction in monthly migraine days, a standard clinical benchmark for successful prevention.

What Attorneys Should Know

One Drug, Two Documented Indications

When an attorney reviews a client's pharmacy records and finds Nurtec ODT appearing both as a filled prescription and as refills at regular intervals, this represents documented treatment for both acute migraine episodes and preventive therapy. The prescription and refill pattern itself tells a clinical story — a patient with ongoing post-traumatic migraine significant enough to require both rescue and prevention from the same drug.

The ODT Formulation Documents Nausea

The choice of an orally dissolving tablet is not incidental. Neurologists prescribe the ODT formulation specifically for patients who experience significant nausea during migraine attacks — nausea so severe that swallowing a tablet may be difficult or impossible. A prescription for Nurtec ODT implicitly documents that the treating physician assessed the patient as having migraine with significant nausea, adding a dimension to the clinical picture.

Monthly Prescription Volume

A patient using Nurtec ODT every other day for prevention fills approximately 15 tablets per month, plus additional tablets for acute breakthrough attacks. Monthly refill records document sustained preventive treatment, with each month representing an ongoing clinical determination that prevention is necessary.

[!KEY] Each monthly Nurtec ODT refill represents an independent clinical decision by the treating neurologist that migraine frequency remains elevated enough to warrant ongoing prevention — twelve months of refills create twelve documented clinical judgments about injury severity that the defense cannot collapse into a single contested assessment.

Brand-Name Only — No Generic Alternative

Rimegepant is available only as Nurtec ODT. There is no generic formulation. The brand-name status is not a prescribing preference — it is the only available option in this specific drug class and formulation.

[!KEY] Because rimegepant has no generic equivalent, a prescriber who writes for Nurtec ODT has no choice but to prescribe brand-name — meaning defense arguments about brand preference inflating claim value have no application here, and the full prescription cost is the only available medication cost for this indication.

Common Questions from Patients

Does Nurtec ODT work quickly? For acute attacks, many patients experience meaningful pain relief within 1-2 hours of taking the tablet. The onset is generally faster than older oral preventive medications taken acutely.

Will I take it every day? If prescribed for prevention only, the regimen is every other day. If you are also experiencing acute attacks, you may take it on intervening days as needed, for a maximum of up to 18 doses per month depending on prescriber guidance.

Can I take it with food? Yes. Nurtec ODT can be taken with or without food.

Conclusion

Nurtec ODT's dual FDA approval — unique in the CGRP class — makes it an especially practical and well-documented option for personal injury patients with post-traumatic migraine. A single prescription can address both the acute attacks that disrupt daily life and the underlying elevated migraine frequency that often follows trauma. For attorneys, it provides a clean, well-documented medication record that reflects both acute and preventive neurological treatment.

For lien-based coverage of Nurtec ODT and other CGRP medications following a personal injury, LienScripts provides pharmacy services for PI patients with repayment from settlement proceeds.

Related Resources

• CGRP Medications: A Complete Guide for Personal Injury
• Qulipta (Atogepant): Preventive Migraine Treatment After a Personal Injury
• Why PI Patients Often Need Multiple Medications
• Migraine and Headache Medications After TBI or Whiplash
• Pharmacy Services for Personal Injury Clients: How It Works
• What Are Medication Liens?